Please ensure Javascript is enabled for purposes of website accessibility

Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)

By Keith Speights - Dec 22, 2017 at 8:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of these two big pharma stocks is the clear winner.

If AbbVie (ABBV -0.39%) and Eli Lilly (LLY -3.01%) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled ahead by a nose. But by September, Lilly would have fallen well behind, with AbbVie kicking dust in its face. As the year draws to a close, AbbVie stock is up more than 55%, while Lilly stock is up close to 17%.

But Dec. 31 isn't the finish line for investors. The race is only warming up. Which of these two big pharma stocks is the better choice over the long run? Here's how AbbVie and Eli Lilly compare.

Two scientists in lab, with one holding dropper and the other looking through a microscope

Image source: Getty Images.

The case for AbbVie

AbbVie ranked as the best big pharma stock over the past three years using several key metrics, including total shareholder return. The most significant reason has been the continued success for Humira. It's the top-selling drug in the world and generates roughly two-thirds of AbbVie's total revenue. While some expected Humira's sales to begin to weaken, that hasn't happened yet. AbbVie expects sales for Humira to increase from $16 billion in 2016 to around $21 billion by 2020. 

Even with sales for Humira growing, though, the drug will become less important for AbbVie over time. Cancer drug Imbruvica is the company's fastest-growing product, with 2017 sales on track to top $2.5 billion. This amount excludes revenue made by Johnson & Johnson, AbbVie's commercialization partner for Imbruvica. 

AbbVie should have another blockbuster with Mavyret. The hepatitis C drug won U.S. and European approval earlier this year. Venclexta, which gained FDA approval in 2016 as a second-line treatment for patients with chronic lymphocytic leukemia who have a chromosomal abnormality called 17p deletion, should be another big winner for AbbVie if it's approved for additional indications. 

That leads to AbbVie's pipeline. The drugmaker has multiple candidates with the potential to generate significant revenue. Humira could be joined by autoimmune-disease drugs upadacitinib and risankizumab. AbbVie has several promising experimental cancer drugs, notably including Rova-T and veliparib. The company awaits FDA approval for elagolix by the second quarter of 2018 in managing endometriosis. Elagolix is also being evaluated in a late-stage study for treating uterine fibroids.

The combination of Humira, Imbruvica, Mavyret, and other potential drugs on the way gives AbbVie a compelling growth story. However, the company should also be attractive to income investors, with its dividend currently yielding 2.9%.

The case for Eli Lilly

Eli Lilly has its own growth drivers. The company has been a longtime leader in the diabetes market. Although Lilly's top-selling insulin injection Humalog is only experiencing slow growth now, sales are soaring for diabetes drug Trulicity. Lilly is also getting help for its endocrinology lineup from osteoporosis drug Forteo.

Another bright spot for Lilly is Taltz. The drug won FDA approval for treating plaque psoriasis in March 2016. Lilly received a green light from the FDA for Taltz as a treatment for psoriatic arthritis earlier this month. Analysts expect the drug to eventually generate annual sales of $1 billion or more. 

While sales are falling for Lilly's older cancer drugs Alimta and Erbitux, Cyramza is enjoying solid growth. The drug has received FDA approval for treating four types of cancer. Lilly is evaluating Cyramza in late-stage studies for treating three other cancer indications. 

The company faces challenges in other areas. Sales have slipped for Cialis and Effient. Slipping is too mild a description for what's happening to sales for Cymbalta, Strattera, and Zyprexa. All three of these neuroscience drugs face generic competition. Still, though, Lilly's newer products have grown sales enough to offset the declines from these older products. 

What about new drugs? Lilly won FDA approval for Verzenio in September for treating breast cancer. The company also awaits regulatory approval for experimental migraine drug galcanezumab. In addition, Lilly's pipeline includes 18 late-stage programs. Another migraine drug, lasmiditan, and pain drug tanezumab stand out as promising new candidates.

Income investors will probably like Lilly's growing dividend. Lilly's board of directors recently approved an 8% dividend increase. The yield currently stands at 2.59%. 

Better stock

There are three main categories investors typically use to pick stocks: growth, income, and valuation. AbbVie has the better growth prospects, in my view, with Humira and Imbruvica continuing to rock along and plenty of promising new drugs on the horizon. AbbVie also wins in the income category with its higher dividend yield.

That leaves only valuation. And AbbVie has an edge there also. Lilly stock trades at more than 18 times expected earnings, while AbbVie's forward earnings multiple is less than 15. 

To me, the choice is clear: AbbVie is the better stock between these two. Actually, looking at all factors, I think AbbVie ranks as the best big pharma stock overall. I expect AbbVie to continue to have plenty of horsepower down the stretch.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$152.54 (-0.39%) $0.60
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$317.41 (-3.01%) $-9.86
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.14 (-2.73%) $-4.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.